Form 4: Rapport Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Krishnaswamy Yeleswaram, Chief Development Officer of Rapport Therapeutics, Inc., sold 404 shares of common stock on August 19, 2026 for $49.90 per share.
Summary
- Open-market sale: disposed of 404 Common Stock at $49.90 ($20,160) on August 19, 2026; holds 246,022 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $20,160 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Krishnaswamy Yeleswaram — Officer (Chief Development Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-19 | Open-market sale | Common Stock | 404 | $50 | $20.2K | 246,022 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-19 | Open-market sale (404 shares) |
Keywords
insider transaction, Form 4, RAPP, Rapport Therapeutics, Inc., bearish, Krishnaswamy Yeleswaram
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.